Your browser version may not work well with NCBI's Web applications. More information
here...
-
- Comment in:
-
Neurology. 2005 May 24;64(10):1824; author reply 1824.
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
Haïk S,
Brandel JP,
Salomon D,
Sazdovitch V,
Delasnerie-Lauprêtre N,
Laplanche JL,
Faucheux BA,
Soubrié C,
Boher E,
Belorgey C,
Hauw JJ,
Alpérovitch A.
Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l'Hôpital, 75651 Paris Cedex 13, France. haik@chups.jussieu.fr
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
PMID: 15623716 [PubMed - indexed for MEDLINE]
-
Related Articles
-
Related Reviews